Skip to main content

Advertisement

SpringerLink
Log in

Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Background

The prostate specific antigen (PSA) test became available in Saskatchewan in 1990 as a part of the provincial health plan. The purpose of this population-based study was to describe the changes in case mix and treatment patterns for prostate cancer following its introduction.

Methods

The Saskatchewan Cancer Registry was used to identify all new cases of prostate cancer for the period 1985–2001. We reviewed over 10,000 charts to collect information on tumor characteristics, diagnostic methods, and first choice of treatment. This information was linked to the demographic and mortality data from the registry.

Results

The age-adjusted incidence of prostate cancer was influenced greatly by PSA testing volumes. Overall, the rate increased from 90.3 per 100,000 in 1985 to 151.3 per 100,000 in 2001. The increase was mostly organ-confined moderately differentiated cases. The incidence rate of metastatic disease dropped about 50% but only in the 70–79 and 80+ age groups. In 1985, 34% of cases were diagnosed by needle biopsy and 60.4% by TURP. In 2001, the values were 76.1% and 19.7%, respectively. More men now choose radical therapy as the first course of treatment, 81% during 1997–2001 compared to only 63.2% in the 1985–1989 period. Mortality rates remained stable in all age groups over these years.

Conclusion

There have been dramatic changes in the case mix of prostate cancers diagnosed since the introduction of PSA testing in the population and significant changes in clinical management of this disease. Thus far, no changes have occurred in mortality rates in the population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Zoorob R, Anderson R, Cefalu C, Sidani M (2001) Cancer screening guidelines. Am Fam Physician 63(6):1101–1112

    PubMed  CAS  Google Scholar 

  2. Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50(1):71–78

    Article  PubMed  Google Scholar 

  3. Skarsgard D, Tonita J (2000) Prostate cancer in Saskatchewan Canada, before and during the PSA era. Cancer Causes Control 11:79–88

    Article  PubMed  CAS  Google Scholar 

  4. Han M, Gann PH, Catalona WJ (2004) Prostate-specific antigen and screening for prostate cancer. Med Clin N Am 88:245–265

    Article  PubMed  CAS  Google Scholar 

  5. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW (2002) Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 60(5):756–759

    Article  PubMed  Google Scholar 

  6. Crawford ED (2003) Epidemiology of prostate cancer. Urology 62(Suppl 6a):3–12

    Article  PubMed  Google Scholar 

  7. Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O’Reilly D, Keane PF, Murray LJ (2004) Evidence of prostate cancer screening in a UK region. BJU Int 93(6):730–734

    Article  PubMed  CAS  Google Scholar 

  8. Horninger W, Berger A, Pelzer A, Klocker H, Oberraigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G (2004) Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 5(3):220–225

    Article  PubMed  Google Scholar 

  9. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (eds) (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva

    Google Scholar 

  10. World Health Organization (1992) International statistical classification of diseases and related health problems tenth revision. World Health Organization, Geneva

    Google Scholar 

  11. National Cancer Institute of Canada (2004) Canadian Cancer Statistics. Toronto, Canada, Ottawa, Ontario, Canada

  12. Statistics Canada. Population reporting an Aboriginal identity, by age group, by provinces and territories (2001 Census). Statistics Canada; 2005 [cited 2005 March 1]. Available from URL:http://www.statcan.ca/english/Pgdb/demo40b.htm

  13. Canadian workshop on screening for prostate cancer, proceedings. Quebec City, Quebec, March 24–27, 1994. Can J Oncol. 4(Suppl 1):1–138

  14. Government of Saskatchewan, Saskatchewan Health (2005) Covered Population 2001: Provincial Population. Saskatchewan Health [cited 2005 March 1]. Available from URL:http://www.health.gov.sk.ca/info_center_publications_covpop2001/skpop.htm

  15. Grossfeld GD, Carroll PR (2001) Prostate cancer early detection: a clinical perspective. Epidemiol Rev 23:173–180

    PubMed  CAS  Google Scholar 

  16. Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23:3–13

    PubMed  CAS  Google Scholar 

  17. Mettlin CJ, Murphy GP, Ho R, Menck HR (1996) The national cancer data base report on longitudinal observations on prostate cancer. Cancer 77(10):2162–2166

    Article  PubMed  CAS  Google Scholar 

  18. Gibbons L, Waters C (2003) Prostate cancer-testing, incidence, surgery and mortality. Health Reports (Statistics Canada, Catalogue 82–003) 14(3):9–20

  19. Escobedo LG, Rivas SD, Holmes MD (2004) Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men. Cancer Detect Prev 28(5):375–380

    Article  PubMed  Google Scholar 

  20. McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD (2004) Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119:174–186

    PubMed  Google Scholar 

  21. Feuer EJ, Merrill RM, Hankey BF (1999) Caner surveillance series: interpreting trends in prostate cancer—Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91:1025–1032

    Article  PubMed  CAS  Google Scholar 

  22. Potosky AL, Feuer EJ, Levin DL (2001) Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 23(1):181–186

    PubMed  CAS  Google Scholar 

  23. Tonita J, Alvi R (2004) Saskatchewan Cancer Control Report 2004 Profiling Cancer in Regional Health Authorities. Regina, Saskatchewan, Canada: Saskatchewan Cancer Agency

  24. Breslow N, Chan CW, Dhom G et al (1977) Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 20:680–688

    Article  PubMed  CAS  Google Scholar 

  25. Smith DS, Catalona WJ (1994) The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152(5 Pt 2):1732–1736

    PubMed  CAS  Google Scholar 

  26. Berny DM (2007) Low Gleason score prostatic adenocarcinomas are no longer viable entities. Histopathology 50:683–690

    Article  Google Scholar 

  27. Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed concservatively for clinically localized prostate cancer. JAMA 280:975–980

    Article  PubMed  Google Scholar 

  28. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexancer FI, ERSPC (2002) Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98(2):268–273

    Article  PubMed  Google Scholar 

  29. de Koning HJ, Auvinen A, Berenguer Sanchez A et al (2002) Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer 97(2):237–244

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saskatchewan Cancer Agency, 400-2631 28th Avenue, Regina, Saskatchewan, Canada, S4S 6X3

    Jon M. Tonita

  2. Tom Baker Cancer Centre, 1331, 29th Street North West, Calgary, Alberta, Canada, T2N 4N2

    David Skarsgard

  3. Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N 5E5

    Nazeem Muhajarine

Authors
  1. Jon M. Tonita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Skarsgard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nazeem Muhajarine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jon M. Tonita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonita, J.M., Skarsgard, D. & Muhajarine, N. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era. Cancer Causes Control 20, 201–209 (2009). https://doi.org/10.1007/s10552-008-9234-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-008-9234-6

Keywords

Search

Navigation